IL-01
Sequence analysis of PSORS1 candidate genes : only HLA-C and corneodesmosin (CDSN) encode proteins unique to the risk haplotype
High-resolution haplotypic refinement of the PSORS1 psoriasis susceptibility locus : FC-02
The development of psoriasiform dermatitis depends on CD18 deficiency of CD4+ CD25+ regulatory T cells in a murine psoriasis model : FC-03
IL-02
Placental growth factor (PlGF) and vascular endothelial growth factor (VEGF) in inflammatory skin disease : FC-04
A pharmacogenetic study of methotrexate and polymorphisms of folate and pyrimidine metabolism in psoriasis : FC-05
Identification of molecular and cellular pathways of autoimmune inflammation through pharmacogenomic study of ciclosporin in psoriasis : FC-06
Identification and characterization of a novel, psoriasis-susceptibility-related, noncoding RNA gene, PRINS : FC-07
Differential expression of antibiotic peptides in psoriasis and eczema : FC-08
Protein expression of TNF-a in psoriatic skin is regulated at a post-transcriptional level by MK2 : FC-09
KL-01
Disease-specific alleles of the MHC class I related gene, MICA, are associated with type I psoriasis and psoriatic arthritis : FC-10
Complex nature of genetic association of psoriasis vulgaris and psoriatic arthritis with SLC12A8 at PSORS5 : FC-11
T-cell clones in psoriatic skin lesions and streptococcal angina share common TCR rearrangements : FC-12
Immunological evidence for increased reactivity to secreted Streptococcus pyogenes proteins in chronic plaque psoriasis : FC-13
Psoriatic CD4+ CD25) effector T cells hyperproliferate in vitro, possess a low activation threshold and are aberrant in their cytokine production : FC-14
IL-03
What clinical trials teach us about the biology of psoriasis : IL-04
Interleukin-20 in human skin organ culture is synthesized by keratinocytes and transferred to epidermal dendritic cells : FC-15
An essential functional role for epidermal T cells in the development of psoriasis : FC-16
Amphiregulin mediates the psoriatic phenotype and induces a T-cell-restricted skin response : FC-17
T cells, immunosurveillance and skin disease : KL-02
Treatment of moderate-to-severe psoriasis with oral dimethyl fumarate (BG00012) : results of a multicentre, randomized, double-blind, placebo-controlled trial
The anti-TNF-α monoclonal antibody, infliximab, effects cellular proliferation and inflammation in psoriatic lesions : FC-19
Previous biological therapies influence the rate of response to etanercept in chronic plaque psoriasis : FC-20
Tumour necrosis factor (TNF) inhibition rapidly downregulates multiple pro-inflammatory pathways in psoriasis plaques : FC-21
Appraising the clinical and cost effectiveness of therapies for inflammatory disease : the NICE way
Role of polymorphic transcription factors in autoimmunity : IL-06
Alefacept induces late-onset apoptosis in infiltrating dermal cells in psoriatic plaques from clinically responsive patients : FC-22
Mitogen- and stress-activated protein kinase 1 is a potential target in the treatment of psoriasis : FC-23
Systemic therapy for psoriasis : ‘plus c¸a change, plus c'est la même chose?’
Polymorphisms of corticotropin-releasing hormone in psoriasis vulgaris : P-01
High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis : P-02
Corticotropin-releasing hormone (CRH), CRH receptor (CRH-R) and NURR1 are increased in psoriasis, further evidence of a brain-skin axis? : P-03
The CX3CL1-CX3CR1 system and psoriasis : P-04
Gene expression profiles of serum-induced abnormal keratinocyte differentiation and regulation of B7-H1 by IFN-γ : P-05
HLA-Cw*0602 is associated with a two-fold higher prevalence of streptococcal throat infection at the onset of both guttate and plaque psoriasis : P-06
PSORS1 : a comparison of HLA-Cw6 and CCHCR1
Value of isolated populations in probing for genes in psoriatic arthritis and psoriasis : P-08
Characterizing susceptibility to phenotypic variations of psoriasis by comparing allelic association signals on chromosome 6 : P-09
P-10
Modulation of the expression of antimicrobial peptides : studies in a xenogeneic transplantation model
Interleukin 20 controls psoriasis induction and maintenance : P-12
Interleukin-20 protein and related receptors in psoriatic skin plaques : P-13
IL-22 regulates the expression of genes responsible for antimicrobial defence, cellular differentiation, and mobility in keratinocytes : a potential role in psoriasis
IL-19, IL-20, and IL-24 : are they regulators of skin inflammation?
In vitro and in situ expression of IL-23 by keratinocytes : enhanced expression in psoriatic lesions
Exogenous IL-1β modulates tight junction claudin expression in vitro : P-17
Correlation of autoimmune phenomena and psoriasis vulgaris : P-18
CD4+CD45RO+CLA+CCR4+CCR10+ T cells obtained from chronic plaque psoriasis (CPP) patients activate autologous mononuclear cells to secrete elevated TNF-a and IL-1β during cell-cell contact : P-19
The expression of HLA-C is reduced in psoriatic skin compared with healthy skin and eczema : P-20
The TLR3-mediated pro-inflammatory response in human keratinocytes is augmented by IFN-a sensitization : relevance for inflammation in psoriasis
Myeloid (CD11c+) dendritic cells are a new inflammatory cell type highly correlated with psoriasis disease activity : P-22
The association of psoriasis with killer cell immunoglobulin-like receptor in the Korean population and the influence of age of onset : P-23
Early psoriatic lesions show a lower lymphatic vessel density but a similar blood vessel density compared with established plaques : P-24
Neuropeptides in psoriasis : P-25
Comparison of calcipotriol 005% (Daivonex) ointment and tazarotene 1% (Zorac) gel in the treatment of plaque psoriasis; a pilot study : P-26
Narrowband UVB decreases mast cell density and downregulates IL-8 expression in psoriatic lesions : P-27
A long-term evaluation of erythema and pigmentation induced by different wavelengths of ultraviolet radiation : P-28
Quantification of erythema induced by TL-01 MED testing : a tool for optimizing dose increments in phototherapy
A comparative study on the effects of treatment with 585-nm pulsed dye laser (PDL) and with UVB-TL-01 in plaque-type psoriasis : P-30
Action mechanism of photochemotherapy (PUVA) in patients with psoriasis : P-31
Efficacy and safety of switch from high- to low-dose topical tacalcitol in combination with bath-PUVA therapy in patients with psoriasis vulgaris : P-32
Ultraviolet light-sparing effect of acitretin in bath PUVA therapy of psoriasis is differentially related to skin types : P-33
Fumaric-acid esters (Fumaderm®) for severe, treatment resistant psoriasis : a prospective, open-label study
Evaluation of possible immune mediators causing flushing after BG00012 (dimethyl fumarate) administration in patients with psoriasis : P-35
Dimethyl fumarate blocks T-cell adhesion to selectins in vitro : P-36
Therapeutic efficacy of soft X-ray therapy in a severe form of nail psoriasis : case report
Effect of naphthalene therapy on proliferative activity, CD4 and CD8 cell count, apoptosis and angiogenesis in the skin of patients with psoriasis : P-38
Initial experience with routine administration of biologicals in psoriasis : P-39
Alefacept rapidly activates gene expression in T-cells, and therapeutic responders show a unique pattern of gene activation : P-40
Efalizumab therapy and incidence of arthropathy adverse events : analysis of pooled data from phase II/III/IV clinical trials
Safety and tolerability of efalizumab therapy : 60 weeks results from a phase 1Mb trial in moderate-to-severe plaque patients with psoriasis
Development of localized papular eruptions during treatment with efalizumab in psoriasis : P-43
Treatment of erythrodermic psoriasis with etanercept : P-44
A review of etanercept in 44 patients with recalcitrant psoriasis : P-45
Etanercept and quality of life in patients with psoriasis : P-46
Reduced T-cell monitoring schedules for patients treated with alefacept : P-47
In situ effects of etanercept therapy in psoriatic lesional skin : reduction in T-cell numbers in association with downregulation of adhesion-molecule expression
Severe psoriasis with chronic active hepatitis C : treatment by etanercept (Enbrel°, Wyeth)
Infliximab for severe, treatment resistant psoriasis : a prospective, open-label study
A phase II study of STA-5326, an oral IL-12 and IL-23 inhibitor, in patients with moderate-to-severe chronic plaque psoriasis (CPP) : P-51
Preliminary histological and gene expression results : an open-label phase II study of STA-5326 in patients with moderate-to-severe chronic plaque chronic plaque psoriasis (CPP)
Preliminary clinical safety and efficacy results from an open-label phase II study of STA-5326, an oral IL-12/IL-23 inhibitor, in patients with moderate-to-severe chronic plaque psoriasis : P-53
Human anti-interleukin IL-12/IL-23 p40 mAb (CNTO1275) inhibits IL-12-induced expression of skin homing molecule, cutaneous lymphocyte antigen and IL-12 receptors on activated peripheral blood T lymphocytes : P-54
Blockade of VLA-2, (alpha2beta1 integrin) inhibits psoriasis in a T-cell-independent manner : P-55
Clearance of lifelong pustular psoriasis with recombinant soluble tumour necrosis alpha receptor (etanercept) treatment : P-56
Pharmacological evaluation of a new potent p38 MAP kinase inhibitor as a systemic drug for psoriasis : P-57
High-dose initiation of etanercept in plaque psoriasis and psoriatic arthritis : an italian experience
Psoriasis therapeutics : the practitioner's view
Patients with psoriatic arthritis have an increased number of lymphocytes in the duodenal mucosa in comparison with patients with psoriasis vulgaris : P-60
Patients with psoriasis and psoriatic arthritis have increased rates of serological markers for gluten sensitivity and coeliac sprue : P-61
Reverse transcriptase activity in psoriatic lesions : effects of reverse transcriptase inhibitors on keratinocyte proliferation and differentiation
Regulation of keratinocyte proliferation by the p63-IKKalpha pathway in psoriasis : P-63
Lithium inhibits the activation of the keratinocyte transglutaminase promoter through a GSK-3β-independent pathway : P-64
The prevalence of psoriasis in patients with alcoholic liver disease : P-65
Diseases associated with psoriasis : P-66
Co-medication in patients with severe psoriasis : first results of a retrospective analysis in 1203 hospitalized patients in Germany
Severe and long-standing psoriasis is associated with an increased prevalence and severity of coronary artery calcification : P-68
Expression of the cleavable precursor peptide of desmocollin 3 in plaque psoriasis : P-69
The coexistence of psoriasis and dermatomyositis; a rare association with therapeutic problems : P-70
Comorbidity of anxiety disorders and sleep problems in patients with psoriasis : P-71
Comorbidity of depressive disorders, substance abuse, and suicidality in patients with psoriasis : P-72
Quality of life in patients with psoriasis : P-73
Improvement in quality of life in psoriasis is correlated with the improvement in psoriasis area and severity index following phototherapy : P-74
Clinical classification of psoriasis vulgaris on the basis of the lesion size : P-75
Altered expression of prohibitin in psoriatic lesion compared with uninvolved skin : P-76
The homocysteine status of patients with psoriasis and its relationship to disease severity : P-77
The memory of parental models and the affective motivational axis in patients diagnosed with psoriasis : P-78
The epidemiological investigation of pruritic patients with psoriasis and the study of pruritogenic factors using confocal laser scanning microscopy : P-79
Efficacy and safety of adalimumab in psoriasis and psoriatic arthritis : ongoing results
Infliximab therapy in plaque-type and arthropathic psoriasis : a long-term observation
Fas mediates lymphocyte induction of psoriasis : P-82